China's biotech sector is on a tear. The Hang Seng Biotech Index has climbed over 60% since Januaryhandily beating China tech ...

The recent experience of Chinese biotech companies in developing their own drug candidates and inking deals with larger ...

US drugmakers are betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

China's biotechnology sector is experiencing notable growth, with the ChinaAMC Hang Seng Biotech ETF, tracking the Hang Seng ...

China's biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds ...

Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

WuXi AppTec (HK: 2359) and WuXi Biologics (HK: 2269) rose 4% and 3.5%, respectively, in Hong Kong trade, extending gains into ...

Big pharmaceutical companies are seeing Chinese biotech as the disruptors. Read more at straitstimes.com. Read more at straitstimes.com.

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...